Accéder au contenu
Merck
Toutes les photos(1)

Documents

45706

Supelco

Warfarine

PESTANAL®, analytical standard

Synonyme(s) :

4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin, Coumafene

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C19H16O4
Numéro CAS:
81-81-2
Poids moléculaire :
308.33
Numéro Beilstein :
8868198
Numéro CE :
201-377-6
Numéro MDL:
MFCD00006854
Code UNSPSC :
41116107
ID de substance PubChem :
329756915
Nomenclature NACRES :
NA.24

Qualité

analytical standard

Niveau de qualité

100

Gamme de produits

PESTANAL®

Durée de conservation

limited shelf life, expiry date on the label

Technique(s)

HPLC: suitable
gas chromatography (GC): suitable

Pf

162-164 °C (lit.)

Application(s)

agriculture
environmental

Format

neat

Chaîne SMILES 

CC(=O)CC(c1ccccc1)C2=C(O)c3ccccc3OC2=O

InChI

1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3

Clé InChI

PJVWKTKQMONHTI-UHFFFAOYSA-N

Informations sur le gène

human ... VKORC1(79001)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Warfarin is an anticoagulant commonly used in the prevention of thrombosis and thromboembolism. Its use is studied in stroke and pulmonary fibrosis patients among many others. It is used to study potential risks and interactions with other drugs and food.

Actions biochimiques/physiologiques

Warfarin consists of a racemic mixture of two active enantiomers, R- and S- forms. Warfarin is slower-acting than the common anticoagulant heparin. Warfarin inhibits the vitamin K-dependent synthesis of biologically active forms of the calcium-dependent clotting factors II, VII, IX and X. It inhibits regulatory factors protein C, protein S, and protein Z.

Attention

Limité aux utilisations professionnelles. Attention − éviter l′exposition − demander les instructions spéciales avant utilisation.

Informations légales

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

Skull and crossbonesHealth hazardEnvironment
GHS06,GHS08,GHS09

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Chronic 2 - Repr. 1A - STOT RE 1 Oral

Organes cibles

Blood

Code de la classe de stockage

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de danger pour l'eau (WGK)

WGK 3

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number
BCCH4004
BCBV7416
BCBV3285
SZBF197XV
SZBC258XV

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 2

1 of 2

Flocoumafen PESTANAL®, analytical standard

Supelco

34084

Flocoumafen

Candesartan Cilexetil Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1854

Candesartan Cilexetil

A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Imre Noth, Kevin J. Anstrom, et al.
American Journal of Respiratory and Critical Care Medicine, 10.1164, 201202-03140C-201202-03140C (2012)
Jack Ansell et al.
Chest, 126(3 Suppl), 204S-233S (2004-09-24)
This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The article describes the antithrombotic effect of VKAs, the monitoring
Shinji Kamisuki et al.
Journal of medicinal chemistry, 54(13), 4923-4927 (2011-05-13)
Fatostatin, a recently discovered small molecule that inhibits activation of sterol regulatory element-binding protein (SREBP), blocks biosynthesis and accumulation of fat in obese mice. We synthesized and evaluated a series of fatostatin derivatives. Our structure-activity relationships led to the identification
Ye Wang et al.
Cardiovascular drugs and therapy, 28(6), 575-585 (2014-10-17)
This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in Singapore. A Markov model was constructed to compare the lifetime costs, quality-adjusted life-years (QALYs)
Matthew W Sherwood et al.
Circulation, 129(18), 1850-1859 (2014-02-21)
During long-term anticoagulation in atrial fibrillation, temporary interruptions (TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been well studied. We sought to determine reasons for TI, the characteristics of patients undergoing TI, and
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique